



Emerald Health Therapeutics Appoints Rebecca Wong as Vice President Quality Affairs

Department head in quality assurance brings over 25 years' pharmaceutical, biotechnology, and medical device industry experience to lead Emerald quality affairs strategy

Victoria, BC, April 3, 2018 – Emerald Health Therapeutics Inc. (TSXV: EMH; OTCQX: EMHTF) (“Emerald”) has appointed Rebecca Wong as Vice President Quality Affairs, with responsibility for quality systems at Emerald’s production and product development facilities. She will ensure Emerald’s systems and products meet Health Canada and international standards and implement traceability and accountability measures to uphold the Company’s commitment to high-quality cannabis products.

“Rebecca has worked exclusively in the rigorous environment of life sciences quality affairs and, impressively, has a flawless inspection record and exemplary reputation with regulators in Canada, the US, and worldwide,” said Chris Wagner, Chief Executive Officer of Emerald. “We believe her contributions to the team will strongly support Emerald’s mission to develop and manufacture value-added, pharmaceutical-grade cannabis products on a global scale.”

Ms. Wong has over 25 years of managerial experience in quality assurance and quality control. She led multiple departments and established systems for vendor qualification, change control, deviations, risk analysis, equipment validation, compliance auditing, document management, and GxP training. Her responsibilities have encompassed quality systems implementation for production and testing, facility accreditation, and inspections in preclinical, clinical, and commercial phases for pharmaceuticals, genetically engineered products, and medical devices.

Prior to joining Emerald, Ms. Wong was Executive Director of Quality Assurance at Novelon Therapeutics (formerly QLT Inc.), reporting to the CEO. She previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.

“I’m pleased to join a dynamic team that already has extensive hands-on experience in clinical research, GMP production practices, regulatory approval processes, and intellectual property creation,” said Ms. Wong. “Emerald has the scientific knowledge base to develop new innovative products and I look forward to applying my experience to further the company’s goal of producing high-quality cannabis products and advancing downstream product development.”

Ms. Wong has been granted an option to acquire up to 150,000 common shares priced at \$5.69 vesting over 3 years. The option expires March 26, 2023.

Join us on our journey of making lives better through cannabis science.

About Emerald Health Therapeutics

Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF) is a Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 500,000 ft² greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 million ft² greenhouse in Delta, BC to grow cannabis. Emerald's team is highly experienced in life sciences, product development and large-scale agribusiness. The company is part of the [Emerald Health Group](#), with multiple companies focused on developing the cannabis and cannabinoid products with potential wellness and medical benefits.

Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill
CFO
(800) 757 3536 Ext. #5

Ray Lagace
Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. As a result, we cannot guarantee that any forward-looking statement will materialize and readers are cautioned not to place undue reliance on these forward looking statements. For more exhaustive information on these risks and uncertainties, the reader should refer to the risk factors described in the management's discussion and analysis for the year ended December 31, 2017. The forward-looking statements contained in this press release represent our expectations as of the date hereof. We disclaim any intention and assume no obligation to update or revise any forward-looking statements. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.